Autophagy activation in COL6 myopathic patients by a low-protein-diet pilot trial

Silvia Castagnaro, Camilla Pellegrini, Massimo Pellegrini, Martina Chrisam, Patrizia Sabatelli, Silvia Toni, Paolo Grumati, Claudio Ripamonti, Loredana Pratelli, Nadir M. Maraldi, Daniela Cocchi, Valeria Righi, Cesare Faldini, Marco Sandri, Paolo Bonaldo, Luciano Merlini

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A pilot clinical trial based on nutritional modulation was designed to assess the efficacy of a one-year low-protein diet in activating autophagy in skeletal muscle of patients affected by COL6/collagen VI-related myopathies. Ullrich congenital muscular dystrophy and Bethlem myopathy are rare inherited muscle disorders caused by mutations of COL6 genes and for which no cure is yet available. Studies in col6 null mice revealed that myofiber degeneration involves autophagy defects and that forced activation of autophagy results in the amelioration of muscle pathology. Seven adult patients affected by COL6 myopathies underwent a controlled low-protein diet for 12 mo and we evaluated the presence of autophagosomes and the mRNA and protein levels for BECN1/Beclin 1 and MAP1LC3B/LC3B in muscle biopsies and blood leukocytes. Safety measures were assessed, including muscle strength, motor and respiratory function, and metabolic parameters. After one y of low-protein diet, autophagic markers were increased in skeletal muscle and blood leukocytes of patients. The treatment was safe as shown by preservation of lean:fat percentage of body composition, muscle strength and function. Moreover, the decreased incidence of myofiber apoptosis indicated benefits in muscle homeostasis, and the metabolic changes pointed at improved mitochondrial function. These data provide evidence that a low-protein diet is able to activate autophagy and is safe and tolerable in patients with COL6 myopathies, pointing at autophagy activation as a potential target for therapeutic applications. In addition, our findings indicate that blood leukocytes are a promising noninvasive tool for monitoring autophagy activation in patients.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalAutophagy
DOIs
Publication statusAccepted/In press - Oct 7 2016

Fingerprint

Protein-Restricted Diet
Autophagy
Muscular Diseases
Leukocytes
Muscle Strength
Muscles
Skeletal Muscle
Body Composition
Homeostasis
Collagen
Fats
Clinical Trials
Apoptosis
Pathology
Biopsy
Safety
Messenger RNA
Mutation
Incidence
Therapeutics

Keywords

  • autophagy
  • Bethlem myopathy
  • clinical trial
  • collagen VI
  • low-protein diet
  • muscular dystrophies
  • Ullrich congenital muscular dystrophy

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Castagnaro, S., Pellegrini, C., Pellegrini, M., Chrisam, M., Sabatelli, P., Toni, S., ... Merlini, L. (Accepted/In press). Autophagy activation in COL6 myopathic patients by a low-protein-diet pilot trial. Autophagy, 1-12. https://doi.org/10.1080/15548627.2016.1231279

Autophagy activation in COL6 myopathic patients by a low-protein-diet pilot trial. / Castagnaro, Silvia; Pellegrini, Camilla; Pellegrini, Massimo; Chrisam, Martina; Sabatelli, Patrizia; Toni, Silvia; Grumati, Paolo; Ripamonti, Claudio; Pratelli, Loredana; Maraldi, Nadir M.; Cocchi, Daniela; Righi, Valeria; Faldini, Cesare; Sandri, Marco; Bonaldo, Paolo; Merlini, Luciano.

In: Autophagy, 07.10.2016, p. 1-12.

Research output: Contribution to journalArticle

Castagnaro, S, Pellegrini, C, Pellegrini, M, Chrisam, M, Sabatelli, P, Toni, S, Grumati, P, Ripamonti, C, Pratelli, L, Maraldi, NM, Cocchi, D, Righi, V, Faldini, C, Sandri, M, Bonaldo, P & Merlini, L 2016, 'Autophagy activation in COL6 myopathic patients by a low-protein-diet pilot trial', Autophagy, pp. 1-12. https://doi.org/10.1080/15548627.2016.1231279
Castagnaro, Silvia ; Pellegrini, Camilla ; Pellegrini, Massimo ; Chrisam, Martina ; Sabatelli, Patrizia ; Toni, Silvia ; Grumati, Paolo ; Ripamonti, Claudio ; Pratelli, Loredana ; Maraldi, Nadir M. ; Cocchi, Daniela ; Righi, Valeria ; Faldini, Cesare ; Sandri, Marco ; Bonaldo, Paolo ; Merlini, Luciano. / Autophagy activation in COL6 myopathic patients by a low-protein-diet pilot trial. In: Autophagy. 2016 ; pp. 1-12.
@article{aeb2fe8ca625400e8e0d04fcbe004a86,
title = "Autophagy activation in COL6 myopathic patients by a low-protein-diet pilot trial",
abstract = "A pilot clinical trial based on nutritional modulation was designed to assess the efficacy of a one-year low-protein diet in activating autophagy in skeletal muscle of patients affected by COL6/collagen VI-related myopathies. Ullrich congenital muscular dystrophy and Bethlem myopathy are rare inherited muscle disorders caused by mutations of COL6 genes and for which no cure is yet available. Studies in col6 null mice revealed that myofiber degeneration involves autophagy defects and that forced activation of autophagy results in the amelioration of muscle pathology. Seven adult patients affected by COL6 myopathies underwent a controlled low-protein diet for 12 mo and we evaluated the presence of autophagosomes and the mRNA and protein levels for BECN1/Beclin 1 and MAP1LC3B/LC3B in muscle biopsies and blood leukocytes. Safety measures were assessed, including muscle strength, motor and respiratory function, and metabolic parameters. After one y of low-protein diet, autophagic markers were increased in skeletal muscle and blood leukocytes of patients. The treatment was safe as shown by preservation of lean:fat percentage of body composition, muscle strength and function. Moreover, the decreased incidence of myofiber apoptosis indicated benefits in muscle homeostasis, and the metabolic changes pointed at improved mitochondrial function. These data provide evidence that a low-protein diet is able to activate autophagy and is safe and tolerable in patients with COL6 myopathies, pointing at autophagy activation as a potential target for therapeutic applications. In addition, our findings indicate that blood leukocytes are a promising noninvasive tool for monitoring autophagy activation in patients.",
keywords = "autophagy, Bethlem myopathy, clinical trial, collagen VI, low-protein diet, muscular dystrophies, Ullrich congenital muscular dystrophy",
author = "Silvia Castagnaro and Camilla Pellegrini and Massimo Pellegrini and Martina Chrisam and Patrizia Sabatelli and Silvia Toni and Paolo Grumati and Claudio Ripamonti and Loredana Pratelli and Maraldi, {Nadir M.} and Daniela Cocchi and Valeria Righi and Cesare Faldini and Marco Sandri and Paolo Bonaldo and Luciano Merlini",
year = "2016",
month = "10",
day = "7",
doi = "10.1080/15548627.2016.1231279",
language = "English",
pages = "1--12",
journal = "Autophagy",
issn = "1554-8627",
publisher = "Taylor and Francis Inc.",

}

TY - JOUR

T1 - Autophagy activation in COL6 myopathic patients by a low-protein-diet pilot trial

AU - Castagnaro, Silvia

AU - Pellegrini, Camilla

AU - Pellegrini, Massimo

AU - Chrisam, Martina

AU - Sabatelli, Patrizia

AU - Toni, Silvia

AU - Grumati, Paolo

AU - Ripamonti, Claudio

AU - Pratelli, Loredana

AU - Maraldi, Nadir M.

AU - Cocchi, Daniela

AU - Righi, Valeria

AU - Faldini, Cesare

AU - Sandri, Marco

AU - Bonaldo, Paolo

AU - Merlini, Luciano

PY - 2016/10/7

Y1 - 2016/10/7

N2 - A pilot clinical trial based on nutritional modulation was designed to assess the efficacy of a one-year low-protein diet in activating autophagy in skeletal muscle of patients affected by COL6/collagen VI-related myopathies. Ullrich congenital muscular dystrophy and Bethlem myopathy are rare inherited muscle disorders caused by mutations of COL6 genes and for which no cure is yet available. Studies in col6 null mice revealed that myofiber degeneration involves autophagy defects and that forced activation of autophagy results in the amelioration of muscle pathology. Seven adult patients affected by COL6 myopathies underwent a controlled low-protein diet for 12 mo and we evaluated the presence of autophagosomes and the mRNA and protein levels for BECN1/Beclin 1 and MAP1LC3B/LC3B in muscle biopsies and blood leukocytes. Safety measures were assessed, including muscle strength, motor and respiratory function, and metabolic parameters. After one y of low-protein diet, autophagic markers were increased in skeletal muscle and blood leukocytes of patients. The treatment was safe as shown by preservation of lean:fat percentage of body composition, muscle strength and function. Moreover, the decreased incidence of myofiber apoptosis indicated benefits in muscle homeostasis, and the metabolic changes pointed at improved mitochondrial function. These data provide evidence that a low-protein diet is able to activate autophagy and is safe and tolerable in patients with COL6 myopathies, pointing at autophagy activation as a potential target for therapeutic applications. In addition, our findings indicate that blood leukocytes are a promising noninvasive tool for monitoring autophagy activation in patients.

AB - A pilot clinical trial based on nutritional modulation was designed to assess the efficacy of a one-year low-protein diet in activating autophagy in skeletal muscle of patients affected by COL6/collagen VI-related myopathies. Ullrich congenital muscular dystrophy and Bethlem myopathy are rare inherited muscle disorders caused by mutations of COL6 genes and for which no cure is yet available. Studies in col6 null mice revealed that myofiber degeneration involves autophagy defects and that forced activation of autophagy results in the amelioration of muscle pathology. Seven adult patients affected by COL6 myopathies underwent a controlled low-protein diet for 12 mo and we evaluated the presence of autophagosomes and the mRNA and protein levels for BECN1/Beclin 1 and MAP1LC3B/LC3B in muscle biopsies and blood leukocytes. Safety measures were assessed, including muscle strength, motor and respiratory function, and metabolic parameters. After one y of low-protein diet, autophagic markers were increased in skeletal muscle and blood leukocytes of patients. The treatment was safe as shown by preservation of lean:fat percentage of body composition, muscle strength and function. Moreover, the decreased incidence of myofiber apoptosis indicated benefits in muscle homeostasis, and the metabolic changes pointed at improved mitochondrial function. These data provide evidence that a low-protein diet is able to activate autophagy and is safe and tolerable in patients with COL6 myopathies, pointing at autophagy activation as a potential target for therapeutic applications. In addition, our findings indicate that blood leukocytes are a promising noninvasive tool for monitoring autophagy activation in patients.

KW - autophagy

KW - Bethlem myopathy

KW - clinical trial

KW - collagen VI

KW - low-protein diet

KW - muscular dystrophies

KW - Ullrich congenital muscular dystrophy

UR - http://www.scopus.com/inward/record.url?scp=84991030742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991030742&partnerID=8YFLogxK

U2 - 10.1080/15548627.2016.1231279

DO - 10.1080/15548627.2016.1231279

M3 - Article

AN - SCOPUS:84991030742

SP - 1

EP - 12

JO - Autophagy

JF - Autophagy

SN - 1554-8627

ER -